NEU — Neuren Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$2.95bn
- AU$2.66bn
- AU$64.63m
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union
Australia's Neuren jumps as EU committee backs key drug authorisation
Brief: Neuren Pharmaceuticals Reassessing Capital Management Options
Brief: Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome
Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination
Brief: Neuren Pharmaceuticals Announces New On-Market Share Buy-Back Program
Australia's Neuren sinks as Rett drug setback prompts Jefferies PT, outlook cuts
Jefferies cuts PT, earnings forecasts on Australia's Neuren after setback for Rett drug in Europe
Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles
Brief: Neuren Pharmaceuticals Seeks Trading Halt
Brief: Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide
Australia's Neuren jumps as partner sees Rett syndrome drug sales hitting $700 mln by 2028
Brief: Neuren Pharmaceuticals Says Health Canada Approves Clinical Trial Application For NNZ-2591
Australia's Neuren Pharma climbs after Canada approves drug trial
Brief: Neuren Pharmaceuticals Says US FDA Approves Daybue Stix (Trofinetide)
Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment